Lb Pharmaceuticals (LBRX) EPS (Basic) (2024 - 2026)

Lb Pharmaceuticals' (LBRX) quarterly EPS (Basic) came in at -$0.67 in Q1 2026, up 95.44% year-on-year from -$0.35 in Q1 2025, and down 139.6% quarter-over-quarter from $1.7 in Q4 2025.

Lb Pharmaceuticals (LBRX) EPS (Basic) (2024 - 2026) Analysis & Trends

Lb Pharmaceuticals' EPS (Basic) history runs 3 years deep, the most recent figure standing at -$0.67 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 95.44% year-over-year to -$0.67 in Q1 2026; TTM through Mar 2026 was -$0.5, a N/A change from a year earlier, with the FY2025 full-year figure at -$0.0, up 98.22% from the prior year.
  • EPS (Basic) eased to -$0.67 in Q1 2026 per LBRX's latest filing, from $1.7 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $161.82 in Q4 2024 and bottomed at -$39.49 in Q3 2024.
  • The 3-year median for EPS (Basic) is -$0.64 (2025), against an average of $17.99.
  • Biggest YoY gain for EPS (Basic) was 98.45% in 2025; the steepest drop was 98.95% in 2025.
  • Year by year, EPS (Basic) stood at $161.82 in 2024, then plunged by 98.95% to $1.7 in 2025, then sank by 139.6% to -$0.67 in 2026.
  • Per Business Quant, the three latest LBRX EPS (Basic) figures stand at -$0.67 (Q1 2026), $1.7 (Q4 2025), and -$0.61 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Basic) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 0.00
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.16
4 NuCana 279.75 Bn 279.75 Bn - 0.00
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 4.06
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 6.99
7 Belite Bio 62.51 Bn 62.51 Bn - 0.00
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 7.59
9 Revolution Medicines 37.78 Bn 37.78 Bn - -2.29
10 Lb Pharmaceuticals 977.73 Mn 977.73 Mn - -0.67

Historic Data

Download Data
DateValue
Mar 31, 2026 -0.67
Dec 31, 2025 1.70
Sep 30, 2025 -0.61
Mar 31, 2025 -14.79
Dec 31, 2024 161.82
Sep 30, 2024 -39.49